In the last twenty years, endovascular technology has revolutionized the management of patients with abdominal aortic aneurysm (AAA) b...
In the last twenty years, endovascular technology has revolutionized the management of patients with abdominal aortic aneurysm (AAA) because of its less invasiveness.
Endovascular stent grafting is a newer form of treatment for Abdominal Aortic Aneurysm that is less invasive than open surgery. Endovascular stent grafting uses an endovascular stent graft to reinforce the wall of the aorta and to help keep the damaged area from rupturing.
The technology has evolved from large profile endoprothesis but requires open-surgery to low profile endoprothesis implantable percutaneously (PEVAR).
Furthermore, the development of different type of endoprothesis and extension has allowed the treatment of more complex abdominal aorta aneurysm. This second websymposium describes the latest low profile endovascular prothesis and its use by our Italian colleagues.
|16:00||Introduction - Prof. Ippoliti|
|16:10||1st Live Procedure - Dr Pratesi / Dr Barbante|
|16:45||The role of low profile AAA stent grafts in expanding EVAR feasibility - Dr Pratesi|
|16:55||2nd Live case - Dr Pratesi / Dr Barbante|
|17:30||What data exists to support the daily use of low profile AAA stent grafts - Dr Pratesi|
|17:40||Q&A. Final Discussion and Debate - Prof. Ippoliti / Dr Pratesi|
|18:00||End of the Webinar|
This webinar is an educational event supported by Cordis Corporation, and is intended for Healthcare Professionals in Europe Middle East and Africa.
The use of the INCRAFT® AAA Stent-Graft System requires that physicians be specially trained in endovascular abdominal aortic aneurysm repair techniques, including experience with high resolution fluoroscopy and radiation safety. Cordis Corporation will provide training specific to the INCRAFT® AAA Stent-Graft System.
The INCRAFT® System is currently approved for investigational device use only in the U.S. and Japan and is being studied in a global pivotal clinical study in the U.S. and Japan called the INSPIRATION Trial, which completed enrollment in 2013.’
While every effort is made to see that no inaccurate or misleading data, opinions, or statements appear in this webinar, Cordis Corporation wish to make it clear that material contained in the webinar represents independent evaluations and opinions of the authors and contributors. As a consequence, Cordis Corporation accepts no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content or the use of any drug or medical device in a way that lies outside its current licensed application in any territory. This presentation may include the demonstration of the use of medical devices; it is not intended to be used as a training guide. The steps demonstrated may not be the complete steps of the procedure. Individual preference and experience, as well as patient needs, may dictate variation in procedure steps. Before using any medical device, including those demonstrated or referenced in this webinar, review all relevant package inserts, with particular attention to the indications, contraindications, warnings and precautions, and steps for use of the device.
All content in these presentations is owned by their authors and is protected by worldwide copyright laws. No modification or further reproduction of the content is permitted.
Prof. Ippoliti, Dr. Pratesi and Dr. Barbante are compensated by and presenting on behalf of Cordis.
©2016 Cardinal Health. All Rights Reserved.
CORDIS, the Cordis LOGO, INCRAFT are trademark or registered trademarks of Cardinal Health.